Obecabtagene Autoleucel

Summary

Obecabtagene Autoleucel (CHEMBL5095440) is an approved gene (ATC L01XL12); indicated across 3 conditions including b-cell acute lymphoblastic leukemia and acute lymphoblastic leukemia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Gene
• ATC class: L01XL12
• Indications: 3 conditions
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095440
Name	Obecabtagene Autoleucel
Type	Gene
Max phase	4
ATC	L01XL12

Also known as: Aucatzyl, AUTO-1, AUTO1, Obecabtagene autoleucel, OBECABTAGENE AUTOLEUCEL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
B-cell acute lymphoblastic leukemia	4	MONDO:0004947	EFO:0000094
acute lymphoblastic leukemia	1	MONDO:0004967	EFO:0000220
neoplasm	1	MONDO:0005070	EFO:0000616

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE2	3
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04404660	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
NCT07053059	PHASE2	RECRUITING	Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)
NCT07053800	PHASE2	RECRUITING	Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis
NCT07400029	PHASE2	RECRUITING	A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia
NCT06173518	PHASE1	RECRUITING	A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).